Prelude Therapeutics
12
1
1
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
25.0%
3 terminated/withdrawn out of 12 trials
72.7%
-13.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Role: lead
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Role: lead
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Role: lead
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Role: lead
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
Role: lead
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Role: lead
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Role: lead
A Study of PRT2527 in Participants With Advanced Solid Tumors
Role: lead
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
Role: lead
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
Role: lead
A Study of PRT1419 in Patients With Advanced Solid Tumors
Role: lead
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
Role: lead
All 12 trials loaded